Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4Terminated 2No longer available 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 2

Conditions

Melanoma 2Colorectal Neoplasms 1Advanced Pancreatic Cancer 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × IMM-101 × Clear all
NCT01539824 2024-11-25

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

Immodulon Therapeutics Ltd

Phase 2 Completed
12 enrolled 6 charts
Gastrointestinal

Colorectal Neoplasms

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Immodulon Therapeutics Ltd

Phase 2 Completed
16 enrolled 14 charts
Dermatologic

Melanoma

NCT01303172 2021-11-10

A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer

Immodulon Therapeutics Ltd

Phase 2 Completed
110 enrolled 14 charts
Gastrointestinal

Advanced Pancreatic Cancer

NCT01308762 2012-12-06

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Immodulon Therapeutics Ltd

Phase 1 Completed
19 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡